SSY Group (HKG:2005) recorded an attributable profit of HK$399 million in the first nine months, down 57% from a year prior, a Tuesday Hong Kong bourse filing said.
Turnover for the three quarters fell 32% to roughly HK$3.1 billion, mainly due to a drop in the sales volume of intravenous infusion solution and turnover from ampoule injections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments